Ropivacaine mesylate is an aminoamide compound, effectively blocks neuropathic pain. Ropivacaine mesylate is an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane. Ropivacaine mesylate inhibits pressure-induces lung endothelial hyperpermeability in models of acute hypertension. References: [1]. Li TF, et al. Epidural sustained release ropivacaine prolongs anti-allodynia and anti-hyperalgesia in developing and established neuropathic pain. PLoS One. 2015 Jan 24;10(1):e0117321. [2]. Milan Patel, et al. Ropivacaine Inhibits Pressure-Induced Lung Endothelial Hyperpermeability in Models of Acute Hypertension. Life Sci. 2019 Apr 1;222:22-28.

纯度：≥98%

CAS：854056-07-8